{"filings":[{"id":442359,"accession_number":"0001628280-26-035061","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-05-14T20:02:06+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo Q1 net loss $31M; cash only into Q3 2026; stock delisted to OTCQB","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net loss $31.0M ($0.08/share) vs $30.6M loss in Q1 2025; revenue dropped to $1.4M from $6.4M.","Cash and cash equivalents $27.6M as of March 31 – expects to fund operations only into Q3 2026.","Common stock delisted from Nasdaq, now trading on OTCQB; hearing to appeal delisting scheduled June 9.","Rolling BLA for Fabry gene therapy ST-920 underway; CMC module completion expected summer 2026 subject to funding.","2026 GAAP operating expense guidance $110M-$130M; company warns guidance depends on securing additional funding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":1442000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90498,"accession_number":"0001628280-26-028128","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo Therapeutics receives Nasdaq delisting notice; trading to be suspended May 5, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq staff determined to delist SGMO due to failure to meet minimum bid price requirement.","Trading will be suspended at open on May 5, 2026; company plans to appeal before Nasdaq Hearings Panel.","Common stock approved for quotation on OTCQB Venture Market starting May 5, 2026 under symbol SGMO.","Company previously received two compliance periods but remained non-compliant with bid price rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100055,"accession_number":"0001628280-26-022006","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo 2025 net loss $122.9M; cash only $20.9M; Fabry BLA rolling submission ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated 2025 net loss $122.9M ($0.44/sh); Q4 loss $37.4M ($0.11/sh).","Revenue in 2025 fell to $39.6M from $57.8M; Q4 revenue $14.2M up from $7.6M, driven by Pfizer and Lilly collaborations.","Cash and equivalents $20.9M as of Dec 31; expects funding into Q3 2026 after recent $25M offering and other receipts.","Rolling BLA submission to FDA for ST-920 (Fabry gene therapy) in progress; CMC module expected summer 2026 subject to funding.","Neurology pipeline advancing: Phase 1/2 STAND study for ST-503 in chronic pain with six sites activated; Eli Lilly capsid license added."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100054,"accession_number":"0001193125-26-036792","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Sangamo raises ~$25M in underwritten offering of common stock and warrants; amends prior warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 35.19M shares + pre-funded warrants for 17.79M shares, each with a purchase warrant for 52.98M shares.","Combined price per share+ warrant is $0.4719; pre-funded warrant+ warrant at $0.4619; gross proceeds ~$25M.","Existing warrants held by investor repriced from $1.00 to $0.4719 and expiration extended to 5.5 years from closing.","Closing expected February 4, 2026; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100053,"accession_number":"0001001233-26-000005","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo: ST-920 Phase 1/2 data positive; FDA agrees to Accelerated Approval path","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed Phase 1/2 STAAR data can support Accelerated Approval using eGFR slope at 52 weeks; rolling BLA started Dec 2025.","Positive mean annualized eGFR slope of 1.965 at Week 52 (95% CI -0.153, 4.083) across 32 patients; Week 104 slope 1.747.","All 15 ERT-naïve patients achieved normal/supraphysiological α-Gal A activity up to 54 months; 18 ERT patients safely withdrew from ERT.","32 of 33 patients completed 52-week follow-up; ST-920 well-tolerated with no discontinuations due to AEs, no TMA or complement activation.","Statistically significant improvements in SF-36 QoL and GSRS diarrhea scores at Week 52; anti-α-Gal A antibodies reduced/eliminated in 9/10 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100052,"accession_number":"0001001233-26-000002","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","5.02"],"status":"ready","headline":"Sangamo reports ~$20.9M preliminary cash; CFO terminates, interim CFO appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and cash equivalents as of Dec 31, 2025: ~$20.9 million (unaudited, subject to change).","CFO Prathyusha Duraibabu's employment terminated effective Feb 2, 2026.","Nikunj Jain (VP Finance, Controller) appointed Interim CFO effective Feb 3, 2026; no additional compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116397,"accession_number":"0001001233-25-000023","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo Q3 net loss $34.9M, revenue $0.6M; advancing Fabry BLA and pain trial enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 consolidated net loss $34.9M ($0.11/sh) vs net income $10.7M ($0.04/sh) in prior year.","Revenue of $0.6M down from $49.4M, mainly due to absence of Genentech collaboration revenue.","Cash and equivalents $29.6M; with Pfizer $6M license fee and ATM proceeds, runway into Q1 2026.","FDA reiterated eGFR slope endpoint for isaralgagene civaparvovec accelerated approval; BLA submission expected as early as Q1 2026.","First two clinical sites activated for Phase 1/2 ST-503 chronic neuropathic pain study; first patient dosing expected in coming months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":25324000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116396,"accession_number":"0001001233-25-000015","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Sangamo gets Nasdaq extension to April 27, 2026 to meet $1.00 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received 180-day extension from Nasdaq until April 27, 2026 to regain minimum bid price compliance.","Must close at $1.00+ for 10 consecutive trading days to cure deficiency.","Original non-compliance notice was dated April 30, 2025; first cure deadline was Oct 27, 2025.","Failure to cure by April 27, 2026 will trigger delisting notice; company may appeal.","No assurance of regaining compliance; shares continue trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132848,"accession_number":"0001001233-25-000013","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sangamo CFO Duraibabu resigns effective Oct 1, stays part-time; Jain new principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Duraibabu resigns effective Oct 1, 2025; transitions to part-time principal financial officer role.","Nikunj Jain, VP Finance & Corporate Controller since 2021, appointed principal accounting officer.","Jain's agreement: annual base salary $347,548; target annual cash bonus 30% of base; eligible for equity awards.","Duraibabu's part-time agreement: base salary $145,188; $160,000 retention bonus payable Jan 31, 2026.","Duraibabu severance limited to change of control; no other severance under plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132847,"accession_number":"0001001233-25-000011","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sangamo Therapeutics CFO Prathyusha Duraibabu resigns, effective Oct 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Duraibabu resigns to become senior leader at a private AI company; not due to any disagreement with Sangamo.","She will transition to part-time employment and remain interim principal financial officer until a successor is appointed.","Company thanks Duraibabu for contributions to strategic collaborations and investment allocations positioning Sangamo as a neurology-focused genomic medicines company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132846,"accession_number":"0001001233-25-000006","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo reports positive eGFR slopes in Phase 1/2 STAAR gene therapy for Fabry; BLA planned Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean annualized eGFR slope of +1.965 mL/min/1.73m2/yr (95% CI: -0.153, 4.083) at 52 weeks across 32 patients.","All 18 patients on ERT at baseline safely withdrew; one later resumed per physician's decision.","69% of patients improved FOS-MSSI severity score at 12 months; SF-36 QoL scores showed statistically significant gains.","BLA submission for isaralgagene civaparvovec targeted Q1 2026 under Accelerated Approval pathway, subject to funding.","Company notes need for substantial additional capital to continue as going concern and advance Fabry program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132845,"accession_number":"0001628280-25-038855","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo reports positive Fabry gene therapy data, Q2 net loss narrows to $20M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive topline from registrational STAAR study: mean annualized eGFR slope +1.965 at 52 weeks across all 32 dosed Fabry patients; FDA agrees as primary basis for accelerated approval.","BLA submission for isaralgagene civaparvovec expected as early as Q1 2026; business development for Fabry commercialization ongoing.","First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain; first patient dosing expected fall 2025, preliminary efficacy data Q4 2026.","Q2 2025 revenue $18.3M (vs $0.3M YoY) driven by Lilly license payment; net loss $20.0M ($0.08 EPS) vs $36.1M ($0.18 EPS) prior year.","Cash $38.3M as of June 30; raised ~$21M net from equity offering; expects funding into Q4 2025; reaffirms 2025 opex guidance $135-155M GAAP."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":24743000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149400,"accession_number":"0001628280-25-032748","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo reports positive Phase 1/2 data for Fabry gene therapy ST-920; BLA plan Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean annualized eGFR slope +1.965 at 52 weeks across 32 patients; +1.747 at 104 weeks for 19 patients.","All 18 patients on ERT at baseline withdrawn from ERT and remain off; α-Gal A activity sustained up to 4.5 years.","Reported eGFR slope compares favorably to Replagal (-2.2), Fabrazyme (-1.5), Galafold (-0.4) in published studies.","Significant SF-36 quality-of-life improvements: role-physical +14.8, vitality +9.6, bodily pain +9.0 at week 52.","No preconditioning required; most adverse events grade 1-2; no safety-related discontinuations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149399,"accession_number":"0001628280-25-031559","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Sangamo stockholders approve 14M share increase to 2018 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share reserve increased by 14,000,000 shares; total now includes 8.8M, 9.9M, 7.9M, 10M, 11M from prior years.","Incentive stock option limit raised to 123,200,000 shares.","All nine director nominees elected, including Courtney Beers, Kenneth Hillan, and H. Stewart Parker.","Advisory say-on-pay approved: 32.8M for, 23.2M against, 1.3M abstentions.","Ratification of Ernst & Young as independent auditor for FY2025 passed with 119.6M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149398,"accession_number":"0001140361-25-018697","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sangamo Therapeutics raises ~$23M in underwritten public offering of common stock and warrants","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Offering of 12.2M shares and pre-funded warrants for 34.4M shares, each with accompanying purchase warrant, at $0.50 unit price.","Gross proceeds expected ~$23M, before underwriting discounts and expenses; closing expected May 14, 2025.","Pre-funded warrants exercisable at $0.01 per share; purchase warrants at $0.75 per share, exercisable after six months for six years.","Sangamo may force exercise of purchase warrants if stock price exceeds $2.75 for ten consecutive trading days after six months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149397,"accession_number":"0001628280-25-022664","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Sangamo receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 30, 2025, Nasdaq notified Sangamo that its stock closed below $1.00 for 30 consecutive business days.","Company has until October 27, 2025 to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant, may qualify for a second 180-day period if other listing standards are met.","Failure to cure could result in delisting from the Nasdaq Capital Market.","Sangamo will monitor bid price and evaluate options including a reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168461,"accession_number":"0001628280-25-013085","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo FY2024 net loss $97.9M; FDA clears ST-503 IND; Fabry BLA path to Accelerated Approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net loss $97.9M ($0.49/share) vs $257.8M ($1.48) in 2023; revenue $57.8M vs $176.2M.","Cash $41.9M at Dec 31, 2024; with $10.1M ATM proceeds and $5M Pfizer payment, funds operations into mid-Q2 2025.","FDA cleared IND for ST-503 (chronic neuropathic pain); patient enrollment expected mid-2025; preliminary efficacy data Q4 2026.","FDA agreed to Accelerated Approval for isaralgagene civaparvovec in Fabry using Phase 1/2 data; BLA submission H2 2025.","License agreements with Genentech (Aug 2024) and Astellas (Dec 2024) for STAC-BBB capsid; $20M upfront from Astellas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168460,"accession_number":"0001628280-25-004197","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sangamo reports updated Phase 1/2 STAAR data for ST-920; eGFR slope +3.061; FDA Accelerated Approval path confirmed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["33 patients treated; gene therapy ST-920 generally well-tolerated; no deaths or discontinuations.","ERT-naïve/pseudo-naïve patients showed sustained α-Gal A activity up to 42 months; 17/18 ERT patients remain off ERT.","23 patients with ≥12 months follow-up: mean annualized eGFR slope +3.061 (95% CI 0.863-5.258), indicating potential kidney improvement.","FDA agreed to Accelerated Approval using 52-week eGFR slope; BLA submission expected H2 2025.","Significant QoL (SF-36 General Health +10.6, p=0.0020) and GI symptom improvements; anti-α-Gal A antibodies reduced/eliminated in 9/10 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185594,"accession_number":"0001628280-24-052579","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Pfizer terminates hemophilia A gene therapy deal with Sangamo; milestone payments lost","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pfizer notified Sangamo of termination for convenience effective April 21, 2025; no BLA or MAA to be submitted.","Sangamo forfeits up to $220M in remaining milestones and all future royalties (14-20% of net sales).","Sangamo receives exclusive license back to develop and commercialize SB-525; Pfizer gets low single digit royalties.","Sangamo plans to seek a new partner to advance regulatory filings for giroctocogene fitelparvovec.","Pfizer had paid $125M already ($70M upfront + $55M milestones); remaining program rights revert."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185593,"accession_number":"0001628280-24-050545","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Sangamo: Phase 3 hemophilia A gene therapy succeeds; share authorization suit resolved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 AFFINE trial met primary endpoint: mean ABRtotal reduced from 4.73 (prophylaxis) to 1.24 post infusion (p=0.004).","84% of participants (42/50) achieved FVIII activity >5% at Month 15; 88% had no treated bleeds.","Safety: no FVIII inhibitors, no treatment-related malignancies; ALT elevations manageable with corticosteroids.","Delaware Court validated share increase vote standard; Sangamo dismissed Section 205 application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185592,"accession_number":"0001628280-24-047099","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo posts Q3 net income $10.7M; FDA clears Accelerated Approval path for Fabry gene therapy ST-920","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $10.7M ($0.04 diluted EPS) vs net loss $104.2M ($0.59 loss) in Q3 2023.","Revenue $49.4M (up from $9.4M), driven by $49.2M from Genentech collaboration.","FDA agrees Phase 1/2 STAAR data can support Accelerated Approval for ST-920 in Fabry disease; BLA submission expected H2 2025.","Received $50M from Genentech upfront/milestones; eligible for up to $1.9B in additional milestones plus tiered royalties.","Cash $39.2M; expects to fund operations into Q1 2025 including $10M milestone from Genentech."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":50249000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185591,"accession_number":"0001628280-24-042308","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sangamo files to validate share increase; stockholder challenge; hearing Dec 12","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Stockholder lawsuit claims wrong voting standard for share increase; company seeks validation.","Sangamo filed Section 205 petition to validate amendment increasing authorized shares from 640M to 960M.","Vote results: 107.95M for (52% of outstanding, 92% of votes cast); both standards met.","Court of Chancery hearing scheduled Dec 12, 2024; opposition due Nov 12.","Company previously warned of going concern risk; validation needed to enable equity fundraising."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202171,"accession_number":"0001628280-24-035160","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo posts Q2 net loss $0.18/sh, cash $27.8M; signs Genentech deal for up to $1.9B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Signed global license with Genentech for zinc finger repressors targeting tau and STAC-BBB capsid; $50M near-term, up to $1.9B milestones plus royalties.","Q2 net loss $36.1M ($0.18/sh) vs $114.5M ($0.66); revenue $0.3M down from $6.8M.","Cash $27.8M at June 30; with Genentech $50M, runway into Q1 2025.","Pfizer's Phase 3 hemophilia A gene therapy met primary endpoint; Sangamo eligible for up to $220M milestones and 14-20% royalties.","Fabry disease: 33 patients dosed, 17 off ERT; eGFR improvement observed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":837000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202170,"accession_number":"0001628280-24-032815","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sangamo Phase 3 hemophilia A gene therapy meets primary endpoint with superiority over prophylaxis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AFFINE trial achieved superiority on total ABR (1.24 vs 4.73, p=0.0040) compared to FVIII prophylaxis.","84% of participants maintained FVIII activity >5% at 15 months; mean treated ABR reduced 98.3% (0.07 vs 4.08, p<0.0001).","Sangamo eligible for up to $220M in regulatory/commercial milestones plus 14%-20% royalties on sales.","One participant (1.3%) returned to prophylaxis; treatment generally well tolerated with transient elevated FVIII in 49.3%.","Pfizer to discuss data with regulatory authorities; Sangamo's first potential commercial medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218228,"accession_number":"0001628280-24-026903","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Sangamo shareholders approve increase in authorized shares and equity plan share reserve at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized common stock increased from 640M to 960M shares (320M increase).","2018 Equity Incentive Plan amended to add 11M shares to the reserve (total available now ~49.3M plus returning shares).","All nine director nominees elected; advisory 'say-on-pay' passed with 101.3M votes for vs 15.1M against.","Ratification of Ernst & Young as independent auditor for FY2024 approved with 151.1M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218227,"accession_number":"0001628280-24-022186","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sangamo Q1 net loss $49.1M on revenue collapse to $0.5M from $158M; cash runway only into Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $49.1M vs net income $21.1M YoY; diluted EPS -$0.27 vs +$0.12.","Revenue fell to $0.5M from $158M, driven by termination of Biogen/Novartis collaborations.","Cash $54.4M at March 31 (down from $81M); raised ~$24M gross via direct offering.","Pfizer expects BLA/MAA submission for hemophilia A gene therapy in early 2025 if mid-2024 pivotal readout positive.","Fabry gene therapy STAAR study fully dosed; seeking collaboration partner before registrational trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":481000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218226,"accession_number":"0001628280-24-019337","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Sangamo receives Nasdaq deficiency notice for bid price below $1 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received April 24, 2024; stock closed below $1 for 30 consecutive business days.","Company has 180 calendar days until October 21, 2024 to regain compliance.","If not compliant, may transfer to Nasdaq Capital Market for an additional 180-day period.","Evaluating options including a potential reverse stock split to cure the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238195,"accession_number":"0001193125-24-076613","cik":1001233,"company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sangamo Therapeutics announces $24M registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 24.8M shares, 3.8M pre-funded warrants, and 28.6M purchase warrants at $0.84/unit.","Gross proceeds expected ~$24.0M; closing on or about March 26, 2024.","Placement agents: Barclays Capital Inc. and Cantor Fitzgerald & Co.; 6% cash fee.","Pre-funded warrant exercise price $0.01; purchase warrant exercise price $1.00 with 5.5-year term.","Lock-Up Agreements from directors and officers restrict share sales for a period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":82857772.01512696,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}